ERBB2 and gastric cancer: HER2-positive advanced gastric cancer patients were randomly chosen, at a 1:1 ratio, to receive a chemotherapy regimen consisting of cisplatin 80 mg/m2 every 3 weeks plus fluoropyrimidine (fluorouracil 800 mg/m2 every 24 h intravenously for 5 days or capecitabine 1000 mg/m2 twice a day for 14 days) for six cycles, or the same chemotherapy in combination with trastuzumab for six cycles followed by trastuzumab monotherapy.